Orthofix Medical Inc.

What they do

Orthofix designs, manufactures, and sells medical technologies for the musculoskeletal system. Its portfolio includes spinal implants, bone growth therapies, biologics, specialized orthopedic solutions, and the 7D FLASH navigation system. The company operates through two reporting segments: Global Spine and Global Limb Reconstruction.

Revenue drivers

• Global Spine — Largest segment, $687.7M in 2025 (83.6% of net sales). Includes Bone Growth Therapies, Spinal Implants, Biologics, and Enabling Technologies. Bone Growth Therapies alone generated $247.2M in 2025, up 5.9%.
• Global Limb Reconstruction — Generated $134.7M in 2025, up 8.4% reported and 5.3% constant currency. U.S. Limb Reconstruction grew 15.8%.
• Spinal Implants, Biologics, and Enabling Technologies — Revenue of $440.5M in 2025, down 0.3% but benefiting from double-digit growth in Spine Fixation (implants excluding motion preservation).

Recent performance

In Q2 2026, net sales were $210.9M, up 3.8% reported and 4.7% pro forma constant currency compared to Q2 2025. Global Limb Reconstruction grew 13.2% reported and 11.0% constant currency; Global Spine grew 3.5% constant currency. Reported net loss was $15.8M; adjusted EBITDA was $20.1M. For the six months ended June 30, 2026, net sales were $407.6M versus $396.8M in the prior-year period.

Strategy

Management is focusing on improving the quality of growth and strengthening commercial productivity. They are discontinuing the M6 artificial disc product lines to reallocate resources to higher-growth opportunities. They are prioritizing Spine Fixation (implants excluding motion preservation) and Global Limb Reconstruction, which are delivering double-digit constant-currency growth. They are also working to stabilize and regain momentum in Biologics. The company raised its full-year 2026 guidance for both net sales and adjusted EBITDA.

Risks

• Medicare reimbursement headwinds — A temporary Medicare reimbursement headwind affected bone growth stimulators in Q2 2026, though management says reimbursement has been restored.
• Continued losses — The company has posted net losses every year from 2021 to 2025, with 2025 net loss of $92.2M, and the risk of ongoing unprofitability remains.
• Product discontinuation — Discontinuing M6 artificial discs could lead to revenue loss and potential related charges or litigation.
• Integration and operational execution — The company is still working through the integration of the 2023 SeaSpine merger, and management describes the transformation as 'a work in progress.'

Outlook

Management expects continued operational progress and has raised full-year 2026 guidance for net sales and adjusted EBITDA. They anticipate that the restoration of Medicare reimbursement for bone growth stimulators will remove a meaningful headwind for the Therapeutic Solutions business in the second half of the year. They are focused on generating durable, profitable growth and improved cash generation.